10.37
Biohaven Ltd stock is traded at $10.37, with a volume of 1.96M.
It is down -0.67% in the last 24 hours and up +8.25% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
See More
Previous Close:
$10.44
Open:
$10.56
24h Volume:
1.96M
Relative Volume:
0.81
Market Cap:
$1.56B
Revenue:
-
Net Income/Loss:
$-738.82M
P/E Ratio:
-1.4899
EPS:
-6.9602
Net Cash Flow:
$-610.15M
1W Performance:
+10.55%
1M Performance:
+8.25%
6M Performance:
-40.26%
1Y Performance:
-44.13%
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BHVN
Biohaven Ltd
|
10.37 | 1.57B | 0 | -738.82M | -610.15M | -6.9602 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-26 | Initiated | Goldman | Buy |
| Jan-21-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-26-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026 (BHVN) - Seeking Alpha
Here is why Biohaven (BHVN) is among the top healthcare stocks insiders are buying - MSN
Biohaven reports details on discovery of BHV-2100 - BioWorld News
Biohaven (BHVN) fuels confidence with encouraging azetukalner data - MSN
BTIG Reiterates Biohaven (BHVN) Buy Recommendation - MSN
Why Institutions Are Turning Bullish on Biohaven—and the Catalyst That Could Unlock Its Value - NAI500
Why Biohaven Stock Crushed it on Monday - Yahoo Finance
FOMO Trade: What is the implied volatility of Biohaven LtdMarket Performance Recap & Real-Time Buy Signal Notifications - baoquankhu1.vn
CCORF Initiates Biohaven(BHVN.US) With Buy Rating, Announces Target Price $21 - Moomoo
Biohaven’s BHV-1450 shows promise for pemphigus vulgaris - BioWorld News
Hedge Fund Bets: How does Biohaven Ltd score in quality rankings2026 Big Picture & Safe Capital Allocation Plans - baoquankhu1.vn
Whale Trades: How does Biohaven Ltd score in quality rankingsWeekly Risk Summary & High Yield Stock Recommendations - baoquankhu1.vn
Here is why Biohaven (BHVN) is Among the Top Healthcare Stocks Insiders Are Buying - Insider Monkey
8 Healthcare Stocks Insiders Are Buying - Insider Monkey
Decliners Report: Is Biohaven Ltd showing insider buyingMarket Movers & Consistent Income Trade Recommendations - baoquankhu1.vn
Entry Recap: Is Biohaven Ltd showing insider buyingMarket Volume Report & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Earnings Update: What is the long term forecast for Biohaven Ltd stock2026 Trends & Technical Pattern Based Signals - baoquankhu1.vn
Understanding the Setup: (BHVN) and Scalable Risk - Stock Traders Daily
BHVN Stock Price, Quote & Chart | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Biohaven Stock Drops 5.3% Amid Market Volatility - National Today
Biohaven (NYSE:BHVN) Trading Down 5.3%Here's Why - MarketBeat
Aug Spikes: What is the long term forecast for Biohaven Ltd stock2026 Update & Consistent Profit Trade Alerts - baoquankhu1.vn
BHVN PE Ratio & Valuation, Is BHVN Overvalued - Intellectia AI
BHVN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart
Why Biohaven (BHVN) Is Up 11.7% After Fully Enrolling Its Phase 2 Obesity Drug Trial - Sahm
Biohaven Ltd. (BHVN) stock price, news, quote and history - Yahoo Finance UK
Citigroup Forecasts Strong Price Appreciation for Biohaven (NYSE:BHVN) Stock - MarketBeat
Citi Maintains Biohaven(BHVN.US) With Buy Rating, Raises Target Price to $17 - Moomoo
BHVN SEC FilingsBiohaven 10-K, 10-Q, 8-K Forms - Stock Titan
Biohaven Ltd. (BHVN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Biohaven (NYSE:BHVN) Shares Up 10.5%Here's Why - MarketBeat
Biohaven Jumps 10.9% Amid Robust Intraday Rally—What’s Driving This Upswing? - Bitget
Biohaven (BHVN) Fuels Confidence With Encouraging Azetukalner Data - Insider Monkey
Biohaven Ltd. (BHVN)’s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy - MSN
Aug Final Week: Can Biohaven Ltd stock outperform in a bear market2026 Price Targets & Smart Investment Allocation Tips - baoquankhu1.vn
Investment Recap: Can Biohaven Ltd deliver alpha2026 Update & Accurate Intraday Trade Tips - baoquankhu1.vn
Biohaven (BHVN) completes enrollment in phase 2 obesity study of taldefgrobep alfa - MSN
Breakout Zone: Can Biohaven Ltd be recession proofDip Buying & Weekly High Return Stock Forecasts - baoquankhu1.vn
Can Biohaven (BHVN) Redefine Obesity Treatment By Targeting Lean Mass Preservation With Taldefgrobep? - Yahoo Finance
Gains Recap: How does Biohaven Ltd score in quality rankingsLayoff News & Detailed Earnings Play Alerts - baoquankhu1.vn
Market Pulse: What are analysts price targets for Biohaven Ltd2026 Volatility Report & Risk Managed Trade Strategies - baoquankhu1.vn
The Technical Signals Behind (BHVN) That Institutions Follow - Stock Traders Daily
Biohaven shares edge higher after completing enrollment in obesity drug trial - MSN
Biohaven (BHVN) Completes Enrollment in Phase 2 Obesity Study of Taldefgrobep Alfa - Insider Monkey
Biohaven (NYSE:BHVN) Trading 6.2% HigherHere's Why - MarketBeat
Can Biohaven (BHVN) Redefine Obesity Treatment By Prioritizing Muscle Preservation Over Pure Weight Loss? - simplywall.st
JPMorgan Chase & Co. Sells 1,236,587 Shares of Biohaven Ltd. $BHVN - marketbeat.com
Assessing Biohaven (BHVN) Valuation As Losses Persist And Price To Book Hits 25x - simplywall.st
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):